Literature DB >> 10905862

Synthesis of (--)-lasubine(I) via a planar chiral [(eta6-arene)Cr(CO)3] complex.

H Ratni1, E P Kündig.   

Abstract

Key steps of the synthesis of the Lythracaea alkaloid (--)-lasubine(I) are the formation of an enantiopure planar chiral arylaldehyde tricarbonylchromium complex and highly diastereoselective aza-Diels-Alder cycloaddition and intramolecular radical cyclization reactions to afford a quinolizidinone intermediate. Ketone reduction, desilylation, and decomplexation yield the enantiomerically pure product.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10905862     DOI: 10.1021/ol991158v

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  5 in total

1.  Aza-[3 + 3] Annulations: A New Unified Strategy in Alkaloid Synthesis.

Authors:  Grant S Buchanan; John B Feltenberger; Richard P Hsung
Journal:  Curr Org Synth       Date:  2010-08-01       Impact factor: 1.975

2.  Asymmetric synthesis of ring functionalized trans-2,6-disubstituted piperidines from N-sulfinyl delta-amino beta-keto phosphonates. total synthesis of (-)-myrtine.

Authors:  Franklin A Davis; He Xu; Junyi Zhang
Journal:  J Org Chem       Date:  2007-02-17       Impact factor: 4.354

3.  A General Approach to the Quinolizidine Alkaloids via an Intramolecular Aza-[3 + 3] Annulation. Synthesis of (±)-2-Deoxy-Lasubine II.

Authors:  Yu Zhang; Aleksey I Gerasyuto; Quincy A Long; Richard P Hsung
Journal:  Synlett       Date:  2008-01-01       Impact factor: 2.454

4.  A convenient allylsilane-N-acyliminium route toward indolizidine and quinolizidine alkaloids.

Authors:  Roland Remuson
Journal:  Beilstein J Org Chem       Date:  2007-10-02       Impact factor: 2.883

5.  Catalytic Asymmetric C-H Arylation of (η6-Arene)Chromium Complexes: Facile Access to Planar-Chiral Phosphines.

Authors:  María Batuecas; Junfei Luo; Ivana Gergelitsová; Katrina Krämer; Daniel Whitaker; Iñigo J Vitorica-Yrezabal; Igor Larrosa
Journal:  ACS Catal       Date:  2019-04-25       Impact factor: 13.084

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.